Encellin is a biotechnology company based in San Francisco. Encellin is developing diabetes therapeutics using insulin responsive cells. Encellin aims to safely replace missing, damaged, or diseased cells in the body with next generation cell transplants.
In type 1 diabetes (T1D), if the cells that measure sugar and secrete insulin are missing, Encelling performs transplants. However, they are done in only the most severe cases.
Encellin is developing a novel thin-film cell encapsulation device for cell-based therapeutics. With an initial focus on diabetes Encellin plans to encapsulate and replace the cells responsible for making insulin, enabling patients to manage their disease, and have better control over their blood glucose levels.
Biotech Startups vs Diabetes: Will Encellin Break the Mould?
Cell Replacement and Type 1 Diabetes: Encellin's Solution
January 2, 2018
Encellin - The Stem Cellar
September 5, 2019
Encellin is Developing a Cell Therapy Technology to Address Type I Diabetes | Medgadget
Grace Wei's Journey from Academia to Encellin Co-Founder and Entrepreneur
October 5, 2020